Frederick Beland Ph.D.

Director, Division of Biochemical Toxicology

Frederick A. Beland, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov

Back to NCTR Principal Investigator page

About | Publications | Division Scientists

Background

Frederick A. Beland received a B.A. degree in biology from The Colorado College and M.S. and Ph.D. degrees in chemistry from Montana State University. Following postdoctoral work in the Ben May Laboratory at the University of Chicago, he was recruited by FDA’s National Center for Toxicological Research (NCTR) to continue his studies in cancer research. These studies, funded primarily by FDA/NCTR and the National Institute of Environmental Health Sciences/National Toxicology Program, have resulted in over 400 publications.

Dr. Beland is an elected member of the American and European Associations for Cancer Research and the American Chemical Society. He has served on various committees of the American Association for Cancer Research and the Division of Chemical Toxicology of the American Chemical Society, and on study sections for the American Cancer Society and the U.S. National Institutes of Health. He has also been a member of working groups for the International Agency for Research to evaluate the carcinogenic risks of various substances to humans.

Research Interests

The focus of Dr. Beland's research has been to assess the carcinogenic potential of chemicals of interest to FDA and to understand the mechanisms responsible for the carcinogenic response. These investigations involve conducting chronic bioassays in experimental animals and conducting in vitro and in vivo mechanistic studies to determine if the responses observed in experimental animals are relevant to humans. An important component of these studies is the elucidation of dose-response relationships that can be used to guide risk assessments. Recent studies have focused on acrylamide, furan, anti-retroviral drugs (e.g., zidovudine and nevirapine), and inorganic arsenic.

Professional Societies/National and International Groups

American Association for Cancer Research
Member
1977 — Present

American Chemical Society (ACS)
Member
2000 — Present

BMC Cancer
Member, Editorial Board
2004 — Present

European Association for Cancer Research
Member
1983 — Present

Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO)
Member, Expert Roster, Joint FAO/WHO Expert Committee on Food Additives (JEFCA)
2016 — Present

International Agency for Research on Cancer (IARC)
Advisory Group to Recommend an Update to the Preamble for IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, IARC
Member
2018

Working Group to Evaluate the Carcinogenic Hazards to Humans. Acrolein, Arecoline and Some Related Compounds, IARC
Chairman, Experimental Carcinogenesis Subgroup
2020

Working Group to Evaluate the Carcinogenic Risks to Humans. Some Chemicals in Food and Consumer Products, IARC
Chairman, Mechanistic and Other Relevant Data Section
2016 — 2017

Selected Publications

Covalent Histone Modification by an Electrophilic Derivative of the Anti-HIV Drug Nevirapine.
Harjivan S.G., Charneira C., Martins I.L., Pereira S.A., Espadas G., Sabidó E., Beland F.A., Marques M.M., and Antunes A.M.M.
Molecules. 2021, 26(5):1349.

Flow Cytometry Analysis of Anti-Polyethylene Glycol Antibodies in Human Plasma.
Fang J.L., Beland F.A., Tang Y., and Roffler S.
Toxicol Rep. 2020, 8:148-154.

Butyrate-Containing Structured Lipids Inhibit RAC1 and Epithelial-to-Mesenchymal Transition Markers: A Chemopreventive Mechanism Against Hepatocarcinogenesis.
de Conti A., Tryndyak V., Heidor R., Jimenez L., Moreno F.S., Beland F.A., Rusyn I., and Pogribny I.P.
J Nutr Biochem. 2020, 86:108496.

Reduction By, Ligand Exchange Among, and Covalent Binding to Glutathione and Cellular Thiols Link Metabolism and Disposition of Dietary Arsenic Species with Toxicity.
Doerge D.R., Twaddle N.C., Churchwell M.I., and Beland F.A.
Environ Int. 2020, 144:106086.

Epigenetic Effects of Low-Level Sodium Arsenite Exposure on Human Liver HepaRG Cells.
Tryndyak V.P., Borowa-Mazgaj B., Steward C.R., Beland F.A., and Pogribny I.P.
Arch Toxicol. 2020, 94(12):3993-4005.

Characterization of the Variability in the Extent of Nonalcoholic Fatty Liver Induced by a High-Fat Diet in the Genetically Diverse Collaborative Cross Mouse Model.
de Conti A., Tryndyak V., Willett R.A., Borowa-Mazgaj B., Watson A., Patton R., Khare S., Muskhelishvili L., Olson G.R., Avigan M.I., Cerniglia C.E., Ross S.A., Sanyal A.J., Beland F.A., Rusyn I., and Pogribny I.P.
FASEB J. 2020, 34(6):7773-7785.

Pharmacokinetics of Oseltamivir Phosphate and Oseltamivir Carboxylate in Non-Pregnant and Pregnant Rhesus Monkeys.
Loukotková L., Basavarajappa M., Lumen A., Roberts R., Mattison D., Morris S.M., Fisher J., Beland F.A., and Gamboa da Costa G.
Regul Toxicol Pharmacol. 2020, 112:104569.

Apoptosis Contributes to the Cytotoxicity Induced by Amodiaquine and its Major Metabolite N-desethylamodiaquine in Hepatic Cells.
Tang Y., Wu Q., Beland F.A., Chen S., and Fang J.L.
Toxicol In Vitro. 2020, 62:104669.

In Vivo Localization and Postmortem Stability of Benzo[a]pyrene-DNA Adducts.
Poirier M.C., Beland F.A., Divi K.V., Damon A.L., Ali M., Vanlandingham M.M., Churchwell M.I., Von Tungeln L.S., Dwyer J.E., Divi R.L., Beauchamp G., and Martineau D.
Environ Mol Mutagen. 2020, 61(2):216-223.

Gene Expression and Cytosine DNA Methylation Alterations in Induced Pluripotent Stem-Cell-Derived Human Hepatocytes Treated with Low Doses of Chemical Carcinogens.
Tryndyak V., Borowa-Mazgaj B., Beland F.A., and Pogribny I.P.
Arch Toxicol. 2019, 93(11):3335-3344.

Metabolism and Disposition of Arsenic Species from Controlled Dosing with Sodium Arsenite in Adult and Neonatal Rhesus Monkeys. VI. Toxicokinetic Studies Following Oral Administration.
Twaddle N.C., Beland F.A., and Doerge D.R.
Food Chem Toxicol. 2019, 133:110760.

Comparative Pharmacokinetic and Biodistribution Study of Two Distinct Squalene-Containing Oil-in-Water Emulsion Adjuvants in H5N1 Influenza Vaccines.
Tegenge M.A., Von Tungeln L.S., Anderson S.A., Mitkus R.J., Vanlandingham M.M., Forshee R.A., and Beland F.A.
Regul Toxicol Pharmacol. 2019, 108:104436.

Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis.
Dreval K., Tryndyak V., de Conti A., Beland F.A., and Pogribny I.P.
Front Genet. 2019, 10:486.

Metabolism and Disposition of Arsenic Species from Controlled Dosing with Dimethylarsinic Acid (DMA^V) in Adult Female CD-1 Mice. V. Toxicokinetic Studies Following Oral and Intravenous Administration.
Twaddle N.C., Vanlandingham M., Beland F.A., and Doerge D.R.
Food Chem Toxicol. 2019, 130:22-31.

Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.
Borowa-Mazgaj B., de Conti A., Tryndyak V., Steward C.R., Jimenez L., Melnyk S., Seneshaw M., Mirshahi F., Rusyn I., Beland F.A., Sanyal A.J., and Pogribny I.P.
Toxicol Sci. 2019, 170(2):273-282.

Experimental and Pan-Cancer Genome Analyses Reveal Widespread Contribution of Acrylamide Exposure to Carcinogenesis in Humans.
Zhivagui M., Ng A.W.T., Ardin M., Churchwell M.I., Pandey M., Renard C., Villar S., Cahais V., Robitaille A., Bouaoun L., Heguy A., Guyton K.Z., Stampfer M.R., McKay J., Hollstein M., Olivier M., Rozen S.G., Beland F.A., Korenjak M., and Zavadil J.
Genome Res. 2019, 29(4):521-531.

Genotoxic and Epigenotoxic Alterations in the Lung and Liver of Mice Induced by Acrylamide: A 28 Day Drinking Water Study.
de Conti A., Tryndyak V., VonTungeln L.S., Churchwell M.I., Beland F.A., Antunes A.M.M., and Pogribny I.P.
Chem Res Toxicol. 2019, 32(5):869-877.